Oregon Public Employees Retirement Fund Purchases 53,387 Shares of Kenvue Inc. $KVUE

Oregon Public Employees Retirement Fund increased its position in Kenvue Inc. (NYSE:KVUE) by 32.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 219,333 shares of the company’s stock after acquiring an additional 53,387 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Kenvue were worth $3,560,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KVUE. Vanguard Group Inc. increased its holdings in shares of Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares in the last quarter. Geode Capital Management LLC increased its holdings in Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after buying an additional 604,953 shares in the last quarter. Independent Franchise Partners LLP raised its position in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after buying an additional 21,886,537 shares during the last quarter. American Century Companies Inc. lifted its stake in Kenvue by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after acquiring an additional 8,436,166 shares during the period. Finally, Norges Bank bought a new position in Kenvue during the 2nd quarter valued at about $537,418,000. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 1.0%

Shares of KVUE stock opened at $16.82 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The company has a market cap of $32.22 billion, a price-to-earnings ratio of 22.42 and a beta of 0.60. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The firm has a fifty day moving average price of $16.90 and a 200-day moving average price of $18.38.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same period last year, the firm earned $0.28 EPS. Kenvue’s revenue for the quarter was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s payout ratio is 110.67%.

Insider Transactions at Kenvue

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were bought at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research analyst reports. The Goldman Sachs Group reduced their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, October 2nd. Redburn Partners set a $22.00 target price on shares of Kenvue in a research note on Friday, September 26th. Evercore ISI set a $18.00 price target on Kenvue in a report on Tuesday, October 28th. JPMorgan Chase & Co. cut their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.